Ultragenyx Pharmaceutical Inc
(LTS:0LIF)
$
42.06
-1.5093 (-3.46%)
Market Cap: 3.88 Bil
Enterprise Value: 3.30 Bil
PE Ratio: 0
PB Ratio: 11.20
GF Score: 79/100 
Ultragenyx Pharmaceutical Inc at Bank of America Healthcare Conference Transcript
May 10, 2022 / 09:40PM GMT
Release Date Price:
$59.9
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst
Hi, everybody, good afternoon, and once again welcome back to the Bank of America Healthcare Conference. I'm Tazeen Ahmad. I'm one of the senior SMID biotech analysts here at the bank. Our next presenting company is Ultragenyx. Sitting with me are 2 really knowledgeable women, Camille and Mardi. I'll let you both introduce yourselves, and then maybe Camille, you can give us -- or Mardi rather, you can give us an overview of the company and then both of you can participate in some more specific Q&A that we have lined up, if that works.
Camille L. Bedrosian
Ultragenyx Pharmaceutical Inc. - Chief Medical Officer & Executive VP
Sounds great. Thank you.
Mardi C. Dier
Ultragenyx Pharmaceutical Inc. - Executive VP & CFO
You want to start?
Camille L. Bedrosian
Ultragenyx Pharmaceutical Inc. - Chief Medical Officer & Executive VP
Okay. Sure. Hi, everyone. I'm Camille
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers